Page 180 - Haematologica Vol. 110 - January 2025

ARTICLE - Multiple myeloma and the risk of infections
C.H. Blimark et al.
multiple myeloma: systematic review and meta-analysis of
randomized controlled trials. PLoS One. 2013;8(5):e64354.
18. Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-
dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11):1055-1066.
19. Teh BW, Harrison SJ, Worth LJ, Spelman T, Thursky KA, Slavin MA. Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy. Br J Haematol. 2015;171(1):100-108.
20. Dumontet C, Hulin C, Dimopoulos MA, et al. A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial. Leukemia. 2018;32(6):1404-1413.
21. Brioli A, Klaus M, Sayer H, et al. The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol. 2019;98(3):713-722.
22. Blimark CH, Turesson I, Genell A, et al. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. Haematologica. 2018;103(3):506-513.
23. Kristinsson SY, Tang M, Pfeiffer RM, et al. Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica. 2012;97(6):854-858.
24. Kristinsson SY, Bjorkholm M, Andersson TM, et al. Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica. 2009;94(12):1714-1720.
25. Ludwig H, Meckl A, Engelhardt M. Compliance with vaccination recommendations among patients with multiple myeloma: a real world experience. HemaSphere. 2021;5(7):e597.
26. Teh BW HS, Slavin MA, Worth LJ. Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy. Eur J Haematol. 2017;98(2):149-153.
27. Sørrig R, Klausen TW, Salomo M, Vangsted A, Gimsing P. Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study. Eur J Haematol. 2019;102(2):182-190.
28. Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW. Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. Clin Lymphoma Myeloma Leuk. 2021;21(7):444-450.e3.
29. Raje NS, Anaissie E, Kumar SK, et al. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022;9(2):e143-e161.
30. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
31. The Swedish Myeloma group. The Swedish national guidelines in multiple myeloma 2024. https://kunskapsbanken. cancercentrum.se/diagnoser/myelom/vardprogram/ Accessed 28th of June 2024.
32. Holmström MO, Gimsing P, Abildgaard N, et al. Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: a study based on the nationwide Danish Myeloma Database. Am J Hematol. 2015;90(4):e73-e74.
33. Thidemann Andersen K, Klausen T, Abildgaard N, et al. Causes of early death in multiple myeloma patients treated with high- dose therapy followed by autologous stem cell transplantation: a study based on the nationwide Danish Multiple Myeloma Registry. Am J Haematol. 2017;92(10):e611-e614.
34. Caravita T, Offidani M, Siniscalchi A, et al. Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations. Eur J of Haematol. 2012;89(3):276-277.
35. Hsu P, Lin TW, Gau JP, et al. Risk of early mortality in patients with newly diagnosed multiple myeloma. Medicine (Baltimore). 2015;94(50):e2305.
36. Moore KLF, Blimark CH, Vangsted AJ, et al. P-167: Real-world elderly myeloma patients: improved survival despite more adverse risk factors than younger patients and RCT populations. A study on behalf of the Nordic Myeloma Study Group. Clin Lymphoma Myeloma Leuk. 2021;21:S127-S128.
Haematologica | 110 January 2025
172